Full history for every metric is available with a Kvantra account

Stock profile
United Therapeutics Corporation logo

United Therapeutics Corporation (UTHR)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
21.1
History
P/E NTM
19.2
Market cap
23.81B
Currency USD
KvantraRankAbout51
IValue50
IIQuality71
IIIMomentum26
Current price
559.10 USD-3.16%
Close 19 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m1,4831,6861,9362,3282,8773,1833,1883,251
Operating profit$m1,5171,322
Net profit$m5154767279851,1951,3351,2311,183
EPS reported$27.8626.46
Operating cashflow per share$35.2433.48
Capex per share$11.7513.17
FCF per share$23.4920.31
Free cash flow$m1,041867
Net debt$m-1,557-2,068
Book value equity$m7,0966,276
Book value per share$148.1138.5
Number of sharesm47.945.3
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx17.4921.13
P/B LTMx3.043.79
P/S LTMx6.787.47
P/FCF LTMx20.7427.46
EV/EBITDA LTMx11.0313.74
EV/Sales LTMx6.306.82
Earnings Yield LTM%5.72%4.73%
FCF Yield%4.82%3.64%
Quality
ROE%18.81%19.18%
ROIC%16.13%16.83%
Operating margin%47.67%41.47%
Gross margin%87.92%86.34%
FCF/Sales%32.70%27.21%
Growth and momentum
EPS Growth YoY%+13.07%+0.27%
Sales Growth YoY%+10.61%+1.89%
Net Income Growth YoY%+11.68%-3.22%
FCF Growth%-3.69%-22.70%
Operating Profit Growth%+10.18%-11.54%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx27.68-
Net Debt/EBITDAx-0.84-0.75
EBIT/Net interestx77.81111.08
Net debt/market cap%-7.21%-8.68%
Net debt/Equityx-0.22-0.33
Gross debt/equityx0.010.00

ETFs that hold United Therapeutics

FundTickerPosition#Weight
iShares Core S&P Mid-Cap ETFIJH30.74%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY30.74%
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMD30.74%
Schwab U.S. Mid-Cap ETFSCHM20.52%
iShares S&P Mid-Cap 400 Growth ETFIJK31.49%
State Street SPDR S&P Biotech ETFXBI91.75%
Invesco S&P MidCap Momentum ETFXMMO52.65%
State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4.L30.74%
Invesco S&P MidCap Quality ETFXMHQ53.06%
Vanguard S&P Mid-Cap 400 ETFIVOO70.68%

Funds with United Therapeutics among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price559.10 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

United Therapeutics Corporation (UTHR)

UTHR · NASDAQ · Healthcare
559.10 USD-3.16%
Sign up to track this stock
Benchmarks
KvantraRank51
Market cap23.81B
P/E NTM19.2
P/E TTM21.1
KvantraRank?51 / 100
Value
50
Quality
71
Momentum
26
Financialsin USD
20242025TTM2026E
ETFs that hold United Therapeutics
FundTickerPosition#Weight
iShares Core S&P Mid-Cap ETFIJH30.74%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY30.74%
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMD30.74%
Schwab U.S. Mid-Cap ETFSCHM20.52%
iShares S&P Mid-Cap 400 Growth ETFIJK31.49%
State Street SPDR S&P Biotech ETFXBI91.75%
Invesco S&P MidCap Momentum ETFXMMO52.65%
State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4.L30.74%
Invesco S&P MidCap Quality ETFXMHQ53.06%
Vanguard S&P Mid-Cap 400 ETFIVOO70.68%

Funds with United Therapeutics among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current559.10 USD
Upside
Price consensus
Last year average price target
Current price559.10 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free